Health Care/Hospital
DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology
* Pioneering Korea's ARPA-H Project: Focused on mRNA Vaccine Room-Temperature Storage and Extra-Long-Term Preservation * Creating a Platform for Prolonged Room-Temperature Storage and Efficient Distribution of mRNA Vaccines SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- OnOctober 30, a Ko...
2024-11-01 21:00
3566
The clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved
SHENZHEN, China, Nov. 1, 2024 /PRNewswire/ -- On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences") and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the "Drug Clinical Trial Approval Notice" approved by th...
2024-11-01 19:04
2332
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update
* HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of430 million KRW. * Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expected inNovember 2024. ROCKVILLE, Md. and SEOUL, Sout...
2024-11-01 19:00
2223
ICANN81 in Istanbul to Address Future of Global Internet Governance
ISTANBUL, Nov. 1, 2024 /PRNewswire/ -- The Internet Corporation for Assigned Names and Numbers (ICANN) will hold its 81st Public Meeting inIstanbul from 9-14 November 2024, hosted by the Information and Communication Technologies Authority (BTK). This event will bring together in-person and virtu...
2024-11-01 18:56
1628
Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director
TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr.Yiu-Lian Fong to the board of directors for Din...
2024-11-01 15:28
1464
PharmaResearch Hosts 5th Global Symposium on 'Rejuran'
* Over 600 Medical Professionals from 25 Countries Participate * Launch of 'IRC' Committee for Rejuran Global Research Team SEONGNAM, South Korea, Nov. 1, 2024 /PRNewswire/ -- PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch ...
2024-11-01 14:01
1545
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, controlled, multicenter Phase III registration study for biliary track tumor. This trial is designed to comp...
2024-11-01 11:34
1434
National Comprehensive Cancer Network Joins with Vietnam National Cancer Hospital to Enhance Cancer Treatment
International collaboration meets in Vietnam to facilitate treatment recommendation guidelines that help people with cancer to live better lives. HANOI, Vietnam, Nov. 1, 2024 /PRNewswire/ -- As part of ongoing work to define and advance high-quality cancer care globally, leaders from the National...
2024-11-01 10:04
2096
CARsgen® U.S. Clinical Holds Lifted by FDA
SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration ("FDA") lifted the clinica...
2024-11-01 09:33
1591
Zepp Health Launches Enhanced Zepp App 9: Elevating Personalized Health and Wellness for Amazfit Users Worldwide
MILPITAS, Calif., Oct. 31, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced the launch of the enhancedZepp App 9. This latest app version is designed to deliver a more personalized health, wellness...
2024-10-31 23:00
2746
Bridging Geographical Boundaries: Abrobo's Groundbreaking Contribution to China Medical Innovation-- the World's First Live Broadcast of Remote Cerebrovascular Interventional Operation on Animal at an Academic Conference
SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- This golden October, great minds gathered to embark on a new chapter of innovation. The 2024 Oriental Conference of Interventional Neurovascology (OCIN 2024), a premier event in neurovascular treatment, was held successfully fromOctober 25th to 27th at the ...
2024-10-31 22:54
8059
HKUST Spearheads Four Large AI Models to Revolutionize Healthcare
HONG KONG, Oct. 31, 2024 /PRNewswire/ -- In a groundbreaking initiative, The Hong Kong University of Science and Technology (HKUST) has unveiled four AI-driven models poised to transform the medical and healthcare fields. These AI models can assist both general and specialist medical practitioner...
2024-10-31 21:46
2106
Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
TAIPEI, Oct. 31, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with DÁVI Farmacêutica ("DÁVI") inPortugal, for exclusive rights to the commercialization of clobetasol propionate oph...
2024-10-31 21:36
1582
The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024
WASHINGTON, Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve P...
2024-10-31 21:00
966
Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services
HONG KONG and SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) received the Digital Health Certification (DHC) and the Continuous Professional Development (CPD) certifications...
2024-10-31 20:14
1342
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
* Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs * Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancemen...
2024-10-31 20:00
1029
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the ...
2024-10-31 19:00
1492
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the imm...
2024-10-31 18:00
1121
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)
* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market * The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordabil...
2024-10-31 14:31
1013
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK
* This approval marks the second international marketing authorization for sugemalimab outside ofChina, following its recent approval by the European Commission. * The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination...
2024-10-31 13:00
1872
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 311 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8699
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5691
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5174
